genetherapy eyes
A BBC item about a new gene therapy for a specific eye sight problemFrom:kees fieggenViews:0 0ratingsTime:02:42More inEducation

See more here:
genetherapy eyes - Video

Recommendation and review posted by Bethany Smith

Human Genetics
ll4.me Human Genetics History of Human Genetics.- Human Genome Sequence and Variation.- Chromosomes.- From Genes to Genomics to Proteomics.- Formal Genetics of Humans: Modes of Inheritance.- Linkage Analysis for Monogenic Traits.- Oligogenic Disease.- Formal Genetics of Humans: Multifactorial Inheritance and Common Diseases.- Lessons from the Genome-Wide Studies for Complex Multifactorial Disorders and Traits.- Epigenetics.- Human Gene Mutation: Mechanisms and Consequences.- Human Hemoglobin.- Human Genetics of Infectious Diseases.- Gene Action: Developmental Genetics.- Cancer Genetics.- The Role of the Epigenome in Human Cancers.- Population Genetic Principles and Human Populations.- Consanguinity, Genetic Drift, and Genetic Diseases in Populations with Reduced Numbers of Founders.- Human Evolution.- Comparative Genomics.- Genetics and Genomics of Human Population Structure.- Genetic Epidemiology.- Pharmacogenetics.- Behavioral Genetics.- The Genetics of Personality.- Mental Retardation and Intellectual Disability.- Genetic Factors in Alzheimer Disease and Dementia.- Genetics of Autism.- The Genetics of Alcoholism and Other Addictive Disorders.- Behavioral Aspects of Chromosomal Variants.- Genetics of Schizophrenia and Bipolar Affective Disorder.- Model Organisms for Human Disorders.- Mouse as a Model for Human Disease.- Caenorhabditis elegans, A Simple Worm: Bridging the Gap Between Traditional And Systems-Level Biology.- Drosophila as a Model for Human Disease.- Human ...From:wilmatessier9854Views:0 0ratingsTime:00:16More inPeople Blogs

Original post:
Human Genetics - Video

Recommendation and review posted by Bethany Smith

Treatment proves safe and effective, helps cancer survivors with chronic dry mouth

These initial results clear the way for additional gene therapy studies in the salivary glands. Although sometimes overlooked, salivary glands present an ideal target for gene therapy. They are easily accessible and, once a gene is introduced, it has no obvious escape route into the bloodstream, where it can have unintended consequences.

"You cannot imagine how fulfilling it is to jot down an idea on a napkin in 1991 and then see it enter a clinical trial and help people.," said Bruce Baum, D.M.D., Ph.D., lead author on the study and recently retired NIDCR scientist who spent the last 21 years moving gene therapy in the salivary glands from the research bench to the clinic. "Can a scientist ask for anything better?"

Baum's interest in helping head and neck cancer survivors dates to the early 1980s. While attending to patients in the NIDCR's Dry Mouth Clinic, Baum encountered numerous people with head and neck cancer who had received radiation therapy to shrink their tumors. The radiation, while effective in treating cancer, had inadvertently damaged nearby salivary glands, compromising their ability to secrete saliva into the mouth.

Baum said he was thoroughly frustrated at the time because he had no effective moisture-restoring treatments to offer most patients. They had beaten cancer, but the radiation had left them with a permanent parched sensation in their mouths that diminished their quality of life and often led to chronic oral problems, such as difficulty swallowing, inflammation, infection, bad breath, and pain.

In the early 1990s, as the first gene-therapy studies entered research clinics, Baum saw an opportunity to make a difference. An initial napkin sketch of the procedure and 15 years of research later, Baum and his colleagues had assembled a compelling scientific case in animal studies that the transferred Aquaporin-1 gene, once expressed, will create new water channels in the impermeable salivary gland cells and allow water to flow through them. After rigorous reviews by NIH and the U. S. Food and Drug Administration, the Phase I protocol was launched and the first patients treated in 2008.

The scientists gave 11 head and neck cancer survivors a single-dose injection of the Aquaporin-1 gene directly into one of their two parotid salivary glands, the largest of the major salivary glands. The gene was packaged in a disabled, non-replicating adenovirus, the cause of the common cold when intact but incapable of causing a cold in this case. As is standard in gene therapy studies, the virus served as the vector, or Trojan horse, to deliver the gene into the cells lining the salivary gland.

The scientists found that five participants had increased levels of saliva secretion, as well as a renewed sense of moisture and lubrication in their mouths, within the study's first 42 days, the period covered in this report. Of the six who didn't benefit from gene therapy, none had serious side effects. The most common side effect was a transient and relatively minor immune response against the disabled adenovirus.

"It is time to evaluate a different vector to deliver the Aquaporin-1 gene, one that will cause only a minimal immune response," said Baum. "But these data will serve as stepping stones for other scientists to improve on this first attempt in the years ahead. The future for applications of gene therapy in the salivary gland is bright."

Originally posted here:
Gene Therapy Can be Performed Safely in the Human Salivary Gland

Recommendation and review posted by Bethany Smith

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today reported that uniQure's Glybera (alipogene tiparvovec) approval by the European Commission, the first gene therapy approval by a major health regulatory authority, represents a significant milestone and validation for the gene therapy industry. Glybera is a treatment for patients diagnosed with an inherited metabolic disease called familial lipoprotein lipase deficiency (LPLD or familial hyperchylomicronemia), who suffer from severe or multiple pancreatitis attacks despite dietary fat restrictions. The European Commission's marketing authorization of Glybera covers all 27 European member states and uniQure plans to apply for regulatory approval in the U.S., Canada and other countries.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

"The EU approval of Glybera represents a major milestone for the global gene therapy industry," stated Christopher J. Reinhard, Chairman and CEO of Cardium. "This is an important step forward for our field and the millions of patients expected to benefit from new and innovative gene-based therapeutics. Gene therapy offers the opportunity to simplify treatments for serious medical problems and to develop new products for which there are no current medical treatments."

Cardium's late-stage gene therapy Generx product candidate (Ad5FGF-4) is a disease-modifying interventional cardiology biologic being developed as a one-time non-surgical treatment for patients with coronary artery disease. Generx can be delivered using a standard cardiac catheter and is capable of promoting and enhancing cardiac perfusion in the heart through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis).

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands nutraceutical business. The Company's lead commercial product, Excellagen topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands develops, markets and sells dietary supplements through established regional and national retailers. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at http://www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that the approval of a gene therapy in Europe will improve the prospects for other gene therapy products; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that our To Go Brands business can be successfully integrated and expanded; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics, Generx, Cardionovo, Tissue Repair, Gene Activated Matrix, GAM, Excellagen, Excellarate, Osteorate, MedPodium, Appexium, Line, Alena, Cerex, D-Sorb, Neo-Energy, Neo-Carb Bloc, Neo-Chill, and Nutra-Appsare trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company. To Go Brands is a trademark of To Go Brands, Inc.

Excerpt from:
European Union's First Gene Therapy Approval Represents Major Advancement For Industry

Recommendation and review posted by Bethany Smith

PRP Vs Stem Cell Therapy
PRP Therapy Vs Stem Cell TherapyFrom:MiamiFootSurgeryViews:4 0ratingsTime:01:23More inHowto Style

More:
PRP Vs Stem Cell Therapy - Video

Recommendation and review posted by simmons

What is stem cell therapy?
What is stem cell therapy?From:MiamiFootSurgeryViews:4 0ratingsTime:00:50More inHowto Style

Read the rest here:
What is stem cell therapy? - Video

Recommendation and review posted by simmons

Stem Cells Doctor in Mexico Shares his Expertise
http://www.mexicohealth.com The video shows a stem cells doctor in Mexico discussing various procedures he specializes in, which notably are multiple sclerosis, brain degenerative disorders, and eye sight rectification. This stem cell specialist has treated over forty patients using cutting edge stem cell therapies. Despite cynical attitudes from different quarters, this doctor represents the vanguard for stem cell treatments for progressively degenerative conditions. To read the transcript and to get a free quote from stem cells doctor in Mexico. Click the link above. Related Searches: Stem Cell Therapy Doctors Mexico, stem cell treatment glaucoma mexico, stem cell therapy brain disorders mexico, stem cell therapy brain injury mexico, stem cell treatment spinal cord MX,From:mexicohealthViews:3 0ratingsTime:04:05More inPeople Blogs

Originally posted here:
Stem Cells Doctor in Mexico Shares his Expertise - Video

Recommendation and review posted by simmons

Stem Cells Treatment in Mexico - Reports You #39;ll Need
http://www.mexicohealth.com The video shows a top stem cell specialist emphasizing the importance of reports and records in devising a sure shot stem cell treatment. Mexico is going where others have feared to tread by investing heavily in stem cell research and development. Not all conditions are curable using stem cells. Some even require a certain degree of faith in your doctor. This doctor has helped more than 40 patients to get up on their feet. Communication is the key, as this doctor points out. If you #39;re mulling over getting a stem cell treatment in Mexico, for yourself or somebody you know, always remember to carry exhaustive reports. To get a free quote, click the link above. Related Searches: stem cell therapy specialists mexico, Stem Cell Treatment for Multiple Sclerosis Mexico, Stem Cell Therapy in Mexico for Chronic Heart Failure, Adult Stem Cell Treatment in Mexico, Stem Cell Therapy for Diabetes Mexico, stem cell treatment for brain damage Mexico, Stem Cell Treatment for Neurodegenerative Conditions mexico, Stem Cell Treatment for Eye Diseases Mexico, Stem Cell Treatment for Heart Conditions Mexico, Stem Cell Therapy for Brain Injury Mexico,From:mexicohealthViews:3 0ratingsTime:02:08More inPeople Blogs

Read the rest here:
Stem Cells Treatment in Mexico - Reports You'll Need - Video

Recommendation and review posted by simmons

PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:08:01More inPeople Blogs

Follow this link:
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video

Recommendation and review posted by simmons

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:09:00More inPeople Blogs

See the rest here:
PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video

Recommendation and review posted by simmons

Public release date: 6-Nov-2012 [ | E-mail | Share ]

Contact: Jill Scoggins jill.scoggins@louisville.edu 502-852-7461 University of Louisville

LOS ANGELES Marked sustained improvement in all patients with zero adverse effects.

For a phase I clinical trial, these results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital today reported just such almost-never-attained data.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. "The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study."

"In all patients, cells with high regenerative reserve were obtained and employed therapeutically," said Anversa, professor of Anaesthesia and Medicine at Brigham and Women's Hospital and Harvard Medical School. "Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results."

The trial called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced about one million for each patient Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

See the original post:
2 years out, patients receiving stem cell therapy show sustained heart function improvement

Recommendation and review posted by simmons

Public release date: 6-Nov-2012 [ | E-mail | Share ]

Contact: Steve Goodyear sgoodyear@mhif.org 952-807-8365 Minneapolis Heart Institute Foundation

MINNEAPOLIS, MN November 6, 2012 Administering autologous stem cells obtained from bone marrow either 3 or 7 days following a heart attack did not improve heart function six months later, reports a new clinical trial supported by the National Institutes of Health. The results of this trial, called TIME (Transplantation In Myocardial Infarction Evaluation), were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation Tuesday, Nov. 6, at the 2012 Scientific Sessions of the American Heart Association in Los Angeles.

The results of this trial mirror a previous, related study (LateTIME) which found that autologous bone marrow stem cell therapy given 2-3 weeks after a heart attack did not improve cardiac recovery. Both TIME and LateTIME were carried out by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"The data presented by TIME do much to advance stem cell therapy research," said Jay Traverse, MD of the Minneapolis Heart Institute Foundation and Principal Investigator of this study. "While this study did not provide a demonstrated cardiac benefit after six months, we still learned a great deal. Together, TIME and Late TIME have shown that stem cell therapy is safe, and they have set a baseline in terms of quantity of stem cells, type of stem cells, and severity of heart attack."

TIME enrolled 120 volunteers (avg. age 57) between July 2008 and February 2011; the participants all had moderate to severe impairment in their left ventricle and had undergone coronary stent placement as treatment for the heart attack. The participants were randomly assigned to one of four groups: day 3 stem cell, day 3 placebo (inactive cells), day 7 stem cell, or day 7 placebo. The CCTRN researchers developed a method of processing and purifying the stem cells from the bone marrow of each volunteer to ensure everyone received a uniform dose (150 million stem cells).

Heart improvement was assessed six months after stem cell therapy by measuring the percentage of blood that gets pumped out of the left ventricle during each contraction (left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six month follow-up in either the Day 3 or Day 7 stem cell groups compared with placebo or with each other; every group showed about a 3 percent improvement in LVEF. However, the researchers found that younger patients randomized to Day 7 had greater improvement in their LVEF compared to their placebo counterparts

"The lack of six-month improvement seen for TIME and, prior to that, LateTIME, does not mean stem cell therapy is not a viable post-heart attack strategy," said Traverse. "Because we have this data we can start to address some parameters; for example this therapy may work better in younger people, or maybe we need to use cells from healthy volunteers (allogeneic) since their cells may provide greater therapeutic benefit. There will also be upcoming studies using novel cell types which we look forward to using in future clinical trials."

###

For further information see:

Excerpt from:
Stem cell therapy using patient's own cells after heart attack does not enhance cardiac recovery

Recommendation and review posted by simmons

MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country.

Stem cell treatment involves the use of adult stem cells to treat a range of diseases.

The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens.

The regulation of laboratories and practitioners involves five key points.

First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses.

Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence.

Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy.

"Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go.

The DOH said consultations with stakeholders are still ongoing, but it expects a set of guidelines to be released by next month.

Visit link:
Stem cell therapy to be regulated in PH

Recommendation and review posted by simmons

Washington, November 7 (ANI): Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat.

No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL.

"The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study," he stated.

The trial - called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy - was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced - about one million for each patient - Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

The researchers reported that in the 20 patients receiving CSCs, LVEF increased from 29 percent to 36 percent at four months following infusion. None of the 13 control patients in the trial received CSCs and this group showed, on average, no improvement.

The beneficial effect of the CSCs persisted and became progressively greater at the one- and two-year mark following infusion. At the one-year mark following infusion, LVEF increased by 8.1 percent, and at the two-year mark, by 12.9 percent.

More here:
Stem cell therapy improves heart function 2 years after heart attack

Recommendation and review posted by simmons

April Flowers for redOrbit.com Your Universe Online

Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients.

The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects.

Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session.

The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans.

The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient, said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study.

In all patients, cells with high regenerative reserve were obtained and employed therapeutically, said Anversa, professor of Anesthesia and Medicine at Brigham and Womens Hospital and Harvard Medical School. Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results.

The Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, or SCIPIO, trial was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower. A normal LVEF reading is 50 percent or higher.

The CSCs, referred to as c-kit positive cells because they express the c-kit protein on their surface, were harvested from 33 patients during coronary artery bypass surgery. The stem cells were then purified and processed so that they could multiply, and once an adequate number was produced about one million for each patient they were reintroduced into the region of the patients heart that suffered scarring during the heart attack.

At four months after infusion, the researchers report that LVEF increased from 29 percent to 36 percent for 200 patients. On average, the 13 control patients who did not receive a CSC infusion showed any improvement.

Originally posted here:
Studies On Stem Cell Therapy After Heart Attack Show Mixed Results

Recommendation and review posted by simmons

RIO DE JANEIRO--(BUSINESS WIRE)--

CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses.

Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz.

ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1.

Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after the procedure. Objective evaluation of stress myocardium perfusion (scintigraphic analysis), after 1 year of follow-up, gave indications of complete myocardial reperfusion in 75% of the patients, says Dr. Nelson Hossne, Medical Director of CellPraxis. Our conclusion was ReACT's specific cell formulation, MonoCell, had a direct correlation to myocardial neoangiogeneses.

About CryopraxisTM (www.cryopraxis.com.br) and CellPraxis (www.cellpraxis.com)

Located at Bio-Rio Biotech Cluster (Rio de Janeiro, Brazil), CryopraxisTM is the pioneer and the largest bank of umbilical cord blood in Brazil and has been in operation since 2001, with approximately 25,000 customers. CellPraxis is a bioengineering company that invests in research projects involving stem cell therapy. Some of these projects are conducted in partnership with institutions like the Federal University of Rio de Janeiro, Federal University of So Paulo, the University of South Florida and Saneron CCEL Therapeutics, Inc. (a USA based biotechnology company dedicated to stem cell research).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

See the rest here:
Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina

Recommendation and review posted by simmons

Biomarkers For Psychiatric Disorders
ll4.me Biomarkers For Psychiatric Disorders Blood and Brain Gene Expression in Major Psychiatric Disorders: A Search for Biomarkers.- Biomarkers in Schizophrenia.- Proteomic strategies for biomarker discovery from differential expression to isoforms to pathways.- Schizophrenia Biomarkers: a means to advance the disease understanding, diagnosis and treatment.- RNA Biomarkers in Schizophrenia.- Metabolomics: a global biochemical approach to the discovery of biomarkers for psychiatric disorders.- Animal models for schizophrenia a brief overview.- Synaptoproteomics of existing and new animal models of depression.- Animal Models for Anxiety Disorders.- Animal Models of affective behaviors and drug addiction.- Neuroimaging biomarkers in schizophrenia.- Sleep EEG provides biomarkers in depression.- Strategies to identify biomarkers for depression.- Pharmacogenetics of antidepressant response.- Perspectives for an integrated biomarker approach to drug discovery and development.- Hunting for peripheral biomarkers to support drug development in psychiatry.- Biomarkers for the development of antidepressant and anxiolytic drugs.- DNA biomarkers for pharmacogenomics and personalized medicine.- Biological modeling in the discovery and validation of cognitive dysfunctions biomarkers. EAN/ISBN : 9780387792514 Publisher(s): Springer, Berlin, Springer US Discussed keywords: Neurologie Format: ePub/PDF Author(s): Turck, Chris W. Blood and Brain Gene Expression in Major Psychiatric Disorders ...From:judybruno986Views:0 0ratingsTime:00:13More inPeople Blogs

More:
Biomarkers For Psychiatric Disorders - Video

Recommendation and review posted by sam

The Science And Business Of Drug Discovery
ll4.me The Science And Business Of Drug Discovery Introduction.- Introduction to Drugs and Drug Targets.- Background to Chemistry of Small and Large Molecules.- Laying the Foundations: Drug Discovery from Antiquity to the Twenty-First Century.- Drug Discovery Pipeline Overview.- Target Discovery.- Medicinal Chemistry.- Biotherapeutics.- Screening for Hits.- Process Chemistry and Formulation.- Preclinical Development.- Clinical Trials.- Regulatory Affairs and Marketing Approval.- Diagnostics and Personalized Medicine.- Putting it All Together: A Drug Development Case History.- Commercial Aspects of Drug Development.- Challenges and Responses.- Technology Transfer Executives.- Recruitment Executives.- Pharmaceutical Translators and Interpreters. EAN/ISBN : 9781441999023 Publisher(s): Springer, Berlin, Springer Science Business Media Format: ePub/PDF Author(s): Zanders, Edward D. Introduction.- Introduction to Drugs and Drug Targets.- Background to Chemistry of Small and Large Molecules.- Laying the Foundations: Drug Discovery from Antiquity to the Twenty-First Century.- DrugFrom:heathernewlon634Views:0 0ratingsTime:00:16More inPeople Blogs

Read the rest here:
The Science And Business Of Drug Discovery - Video

Recommendation and review posted by sam

Personalized Medicine via Genomic Sequencing - Dr. Hajduk Interview Part 1
Personalized Medicine via Genomic SequencingFrom:Viral PatelViews:14 0ratingsTime:04:00More inScience Technology

Read more from the original source:
Personalized Medicine via Genomic Sequencing - Dr. Hajduk Interview Part 1 - Video

Recommendation and review posted by sam

Personalized Medicine via Genomic Sequening - Dr. Hajduk Interview Part 2
Personalized Medicine via Genomic SequeningFrom:Viral PatelViews:7 0ratingsTime:03:57More inScience Technology

More:
Personalized Medicine via Genomic Sequening - Dr. Hajduk Interview Part 2 - Video

Recommendation and review posted by sam

Dr. Marie Davidian at Elon University #39;s Voices of Discovery
Dr. Marie Davidian, professor of statistics at NC State University, explains how statistical analysis of data can determine what personalized treatment option is best for a patient. Davidian spoke about personalized medicine at Elon University #39;s Voices of Discovery lecture on Nov. 5, 2012.From:Kyra GemberlingViews:1 0ratingsTime:00:38More inEducation

Read the original post:
Dr. Marie Davidian at Elon University's Voices of Discovery - Video

Recommendation and review posted by sam

Personalized Medicine via Genomic Sequencing - Dr. Hajduk Interview Part 3
Personalized Medicine via Genomic SequencingFrom:Viral PatelViews:0 0ratingsTime:03:41More inScience Technology

Read the original post:
Personalized Medicine via Genomic Sequencing - Dr. Hajduk Interview Part 3 - Video

Recommendation and review posted by sam

Eight European researchers develop Ion AmpliSeq Community Panel for lung and colon cancer
Life Technologies Ion AmpliSeq trade; Community Panels are a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited disease. One of the first panels was developed by eight leading European researchers who worked together with Life Technologies scientists to develop a 22-gene Ion AmpliSeq trade; Community Panel for lung and colon cancer. The panel analyzes more than 500 mutations in a single-tube assay that requires just 10 ng of DNA input per primer pool, about 25-fold less than alternative gene panel approaches. The Ion AmpliSeq trade; workflow is a simple PCR reaction that takes just 3.5 hours turn-around time. "Using classical methods to screen for mutations one at a time requires so much DNA sample, you often can #39;t look at all the mutations you want," said Dr. Pierre Laurent-Puig, MD, Ph.D., Professor at the Paris - Descartes University Medical School and a member of the OncoNetwork Consortium. "We have developed a tool that allows us to characterize tumors very easily, using only 10 ng of sample to screen more than 500 COSMIC mutations. Having these kits in our hands will accelerate throughput of the characterization of tumors and make personalized medicine a reality." The research institutions that developed the panel -- dubbed the OncoNetwork -- include Centro Ricerche Oncologiche Mercogliano, Italy; Leiter Genetik / Molekularbiologie ...From:iontorrentViews:9 0ratingsTime:05:38More inScience Technology

Go here to read the rest:
Eight European researchers develop Ion AmpliSeq Community Panel for lung and colon cancer - Video

Recommendation and review posted by sam

BERKELEY HEIGHTS, N.J., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) (Cyclacel or the Company), announced today multiple posters presented on the Company's sapacitabine and on its Polo-Like Kinase 1 (Plk1) inhibitors during the 8th National Cancer Research Institute (NCRI) Cancer Conference being held November 4-7, 2012, Liverpool, United Kingdom.

Sapacitabine:

"Sapacitabine efficacy is enhanced in homologous recombination defective tumours" Date/Time: Tuesday November 6, 2012, 8:30 -- 17:30 Greenwich Mean Time Poster Number: B21

Cyclacel researchers reported that in vitro studies of sapacitabine's active metabolite CNDAC showed that sapacitabine may be effective in patients with mutations of the breast cancer susceptibility proteins BRCA1/2 or homologous recombination repair (HRR)-deficient tumors, such as subsets of triple negative breast, ovarian, colon and non-small cell lung cancer (NSCLC). In addition, CNDAC synergized with either PARP inhibitors or cisplatin in both NSCLC and ovarian cancer cell lines. Cyclacel's cyclin-dependent kinase (CDK) inhibitor seliciclib reduces expression of BRCA1 and BRCA2 and can potentiate sapacitabine/CNDAC activity, as well as other agents enhanced in double strand break (DSB) repair-defective backgrounds. Sapacitabine treatment in combination with seliciclib is currently under investigation in a Phase 1 trial in patients with solid tumors at the Dana Farber Cancer Institute (Boston, MA).

"Therapeutic potential of sapacitabine in cancers defective in homologous recombination" Date/Time: Tuesday November 6, 2012, 8:30 -- 17:30 Greenwich Mean Time Poster Number: B207

Cyclacel collaborators from the Northern Institute for Cancer Research, Newcastle University, UK reported confirmation that ovarian and breast cancer cell lines defective in HRR are highly sensitive to CNDAC, supporting a possible role for sapacitabine/CNDAC in HRR-defective diseases. Primary ovarian cancer samples were also highly sensitive to CNDAC, and correlation of HRR status with CNDAC sensitivity is being assessed.

The studies further support the potential for sapacitabine to be used alone or in combinations to treat HRR- defective tumors, such as ATM- or BRCA-defective tumors. An investigator-sponsored Phase 2 study of sapacitabine in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) with deletion 11q22-23 is ongoing at The University of Texas MD Anderson Cancer Center (Houston, TX). A Phase 1, study of sapacitabine in combination with seliciclib in patients with advanced solid tumors, is ongoing at the Dana Farber Cancer Institute (Boston, MA). As reported at the American Society of Clinical Oncology 2012 annual meeting among 19 patients in this study treated at the recommended Phase 2 doses, 3 with advanced breast, ovarian and pancreatic cancer achieved partial responses (PRs) and 1 with ovarian cancer showed stable disease. All 4 responding patients were reported by the investigator to be BRCA defective.

Polo-Like Kinase 1 (Plk1) inhibitors:

"Parameters improving the therapeutic window of Compound 4, a potent and selective Polo-like kinase 1 inhibitor: in vitro studies" Date/Time: Tuesday November 6, 2012, 8:30 -- 17:30 Greenwich Mean Time Poster Number: B15

Cyclacel scientists and academic collaborators reported the biological characterization of Compound 4, a potent and selective, preclinical-stage, Plk1 inhibitor, selected for further development from Cyclacel's novel Plk1 inhibitor series. In a panel of esophageal cancer cell lines, sensitivity to Compound 4 correlated with p53 status. Esophageal cell lines lacking functional p53 showed the greatest sensitivity to Compound 4. Short drug exposure times demonstrated differential sensitivity between cancerous esophageal cells versus control, outlining the potential broad therapeutic index for Compound 4 in treating esophageal cancers, and in particular those with non-functional p53. Status of p53 could be used as a predictive biomarker in clinical trials to identify responders.

See the original post:
Personalized Medicine Potential of Cyclacel's Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer ...

Recommendation and review posted by sam

Public release date: 6-Nov-2012 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society

WASHINGTON, Nov. 6, 2012 Personalized medicine the promise of customizing treatments that will work best for each individual patient could get a boost from advances in understanding how the proteins that help determine health and disease take the three-dimensional shapes needed to work in the body. That's the message of the latest episode of the 2012 edition of a popular video series from the American Chemical Society (ACS), the world's largest scientific society. The videos are available at http://www.acs.org/PrizedScience and on DVD.

Titled Prized Science: How the Science Behind American Chemical Society Awards Impacts Your Life, the final episode of the 2012 series features the research of Peter Wolynes, Ph.D., winner of the 2012 ACS Award in Theoretical Chemistry. The award is sponsored by Dell Incorporated. Wolynes is a professor at Rice University.

The award recognizes Wolynes' research on proteins, those workhorses of human cells that carry out the instructions from the genetic material DNA. His research aims to help scientists understand how proteins fold into the correct architecture to keep the body healthy and functioning properly. When proteins do not take the right shape, illnesses, such as Alzheimer's disease, can develop. Even slight changes in a protein can have major effects on health, and understanding how this happens could help in the development of personalized medicine.

The premiere episode of Prized Science features Robert Langer, Sc.D., winner of the 2012 ACS Priestley Medal. The video explains Langer's pioneering work making body tissues in the lab by growing cells on special pieces of plastic. Langer's team has used the approach to make skin for burn patients, for instance, with the goal of eventually making whole organs for transplantation.

Other episodes feature Chad Mirkin, Ph.D., winner of the 2012 ACS Award for Creative Invention; Vicki Grassian, Ph.D., winner of the 2012 ACS Award for Creative Advances in Environmental Science and Technology; and Diane Bunce, Ph.D., winner of the 2012 ACS George C. Pimentel Award in Chemical Education.

ACS encourages educators, schools, museums, science centers, news organizations and others to embed links to Prized Science on their websites. The videos discuss scientific research in non-technical language for general audiences. New episodes in the series, which focuses on ACS' 2012 national award recipients, will be issued periodically.

The 2012 edition of Prized Science is completely refreshed, with a new look and feel, with renowned scientists telling the story of their own research and its impact and potential impact on everyday life. Colorful graphics and images visually explain the award recipient's research.

###

Visit link:
Personalizing medicine: New American Chemical Society Prized Science video

Recommendation and review posted by sam